- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03389958
Maternity Care and Contraception (COMSE)
Safe Maternity Care Through Immediate Provision of Highly-effective Postpartum Contraception
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This pre- post-intervention study will take place in Colombia, South America in 2 cities: Medellin (2 sites and Cartagena 1 site). The main objective is to determine the proportion of contraceptive usage by women who have just had a baby, before and after the introduction of specialized contraceptive counseling into maternity care and availability of the most effective contraceptive methods:
Group 1 (Standard of care) participants will be asked about intention for contraception usage upon hospital discharge after maternity care.
Group 2 (Intervention) participants will receive standardized contraceptive counseling and immediate access to the method of choice, including long acting reversible contraception (LARC) and other locally available methods. LARC methods available in Colombia include the copper-T intrauterine device (IUD) and Jadelle® implant, both of which are safe for usage in postpartum women.
Both groups will undergo follow- up via phone at 6-8 weeks, and 6 and 12 months postpartum to determine contraceptive continuation, repeat pregnancy, and to track any complications with the usage of LARC, including infection and contraceptive failure. For subjects with an IUD, an additional visit would take place at 8-10 days to determine need for IUD string trimming and visualization of strings.
The intervention will include introduction of specialized standardized contraceptive counseling to occur during inpatient maternity care and immediate postpartum availability of LARC methods. Currently, contraceptive counseling is left to the postpartum primary care setting and obstetric providers are not trained for immediate IUD placement. LARC devices are not typically available in the inpatient setting. Providers and staff of all levels will be trained in standardized contraceptive counseling methods. Obstetric providers will be trained in immediate postplacental IUD insertion. Staff nurses and providers will have access to company-sponsored implant insertion training programs.
The proportion of participants using LARC methods after implementation of the intervention will be compared to the proportion choosing LARC prior to the intervention. Additionally, the outcomes of women choosing non-LARC methods will be compared to those choosing LARC methods.
The study has received funding by the Colombian grant agency, Colciencias. Regulatory oversight has previously been granted by the University of Antioquia's (Medellin, Colombia) Institutional Review Board. Research operations are managed by the local Colombian organization, NACER, with support of research design and methods, statistical analysis, and medical expertise and trainings provided by clinicians from OHSU. Day to day research operations will be managed by research coordinators at each of the three maternity care hospital sites with support and monitoring by NACER and by OHSU clinicians.
The role of OHSU clinicians will be to provide research infrastructure and clinical support via remote communications, to provide initial training of trainers, to provide monitoring of recruitment and counseling methods, to help in the creation and monitor quality of data collection forms, and to perform statistical analyses. OHSU will not participate in recruitment of participants or in clinical procedures. We do not plan to be present at any research sites in person, though may perform monitoring visits if funds are available.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Cartagena, Colombia
- Maternidad Rafael Calvo
-
Medellín, Colombia
- Metrosalud Manrique
-
Medellín, Colombia
- Hospital General de Medellin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Pregnant woman in labor
- Live fetus over 20 weeks gestation
- Age >14 years
Exclusion Criteria:
- No medical exclusions for the contraceptive method chosen
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of women receiving immediate postpartum long-acting contraception
Time Frame: Through hospital discharge (an average of 3 days)
|
The proportion of women who receive immediate long-acting contraception prior to hospital discharge following the intervention phase of training and availability of devices will be compared to a baseline group prior to the implementation.
|
Through hospital discharge (an average of 3 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Continuation of long-acting contraception placed immediately postpartum
Time Frame: 6, 12 and 18 months postpartum
|
Phone followup will be used to determine the proportion of women who are continuing their contraceptive method
|
6, 12 and 18 months postpartum
|
|
Complications of contraception
Time Frame: 6, 12 and 18 months postpartum
|
Phone followup will be used to determine the proportion of women who have experienced any complications from contraception
|
6, 12 and 18 months postpartum
|
|
Comparison of long-acting methods to short-acting methods
Time Frame: 6, 12, and 18 months postpartum
|
Outcomes (pregnancy, discontinuation) of women choosing long-acting methods will be compared to short-acting methods, coital dependent methods, or no method
|
6, 12, and 18 months postpartum
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11331 (DAIDS ES Registry Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregnancy Related
-
The University of Texas Health Science Center at...The University of Texas at San AntonioCompleted
-
Gynuity Health ProjectsCuidado Integral de la Mujer, Gineclinic, S.C.; Servicios de Salud Medieg,...Not yet recruitingPregnancy Related | Pregnancy Early
-
4YouandMeCambridge Cognition Ltd; Sema4; Evidation Health; Vector Institute of Artificial... and other collaboratorsCompletedPregnancy Related | Wearables | Pregnancy EarlyUnited States
-
The University of Texas Health Science Center,...CompletedPregnancy Related | Pregnancy, High RiskUnited States
-
Peking Union Medical College HospitalPeking Union Medical CollegeUnknownPregnancy | Pregnancy Related | Infant | Pregnancy Disease | Risk FactorChina
-
Shaare Zedek Medical CenterUnknownPregnancy Related | Pregnancy, High Risk | Anesthesia
-
Portucalense UniversityAveiro University; Unidade Local de Saúde do Alto Ave, EPERecruiting
-
Oregon Health and Science UniversityNot yet recruitingPregnancy Related
-
Oregon Health and Science UniversityRecruiting
-
Biorithm Pte LtdNot yet recruitingPregnancy Related
Clinical Trials on Counseling and provision of contraception
-
Children's Hospital of PhiladelphiaEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedContraception Behavior | Pregnancy in Adolescence | CounselingUnited States
-
University of California, San DiegoCompletedContraception | Contraception Behavior | Chemical Teratogen ExposureUnited States
-
Children's Hospital Medical Center, CincinnatiOhio Injury Prevention Partnership; Whitney Strong OrganizationCompletedMental Health Issue | Suicide and Self-harm | Pediatric Emergency Medicine | Firearm InjuryUnited States
-
University of PittsburghCompletedSexually Transmitted Diseases | ContraceptionUnited States
-
University of New MexicoSociety of Family PlanningCompleted
-
Burcu Dişli OktarCompletedContraception UseTurkey (Türkiye)
-
University of UtahCompletedMethod of Contraception | Preterm Birth RecurrenceUnited States
-
Sohag UniversityCompleted
-
Marcos Vera HernandezEvidence Action; MaiMwanaCompleted
-
Boston Children's HospitalNational Heart, Lung, and Blood Institute (NHLBI)Completed